. Overview Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors ("GPCRs") to treat obesity, overweight, and metabolic disorders. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 ("CB1")a key GPCR involved in metabolic regulation. Except where the context indicates otherwise, references to "we," "us," "our," "Skye" or the" Co...
expected 2026-11-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-10 | 2025-12-31 | 0001628280-26-016394 | EDGAR | 79K words |
| 2025-03-20 | 2024-12-31 | 0001516551-25-000027 | EDGAR | — |
| 2024-03-22 | 2023-12-31 | 0001516551-24-000048 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001516551-23-000038 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0001516551-22-000004 | EDGAR | — |
| 2021-03-02 | 2020-12-31 | 0001640334-21-000483 | EDGAR | — |
| 2020-03-23 | 2019-12-31 | 0001640334-20-000582 | EDGAR | — |
| 2019-03-14 | 2018-12-31 | 0001640334-19-000379 | EDGAR | — |
| 2018-03-19 | 2017-12-31 | 0001640334-18-000482 | EDGAR | — |
| 2017-03-10 | 2016-12-31 | 0001640334-17-000456 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001628280-26-056968 | EDGAR | — |
| 2025-11-10 | 2025-09-30 | 0001628280-25-051031 | EDGAR | 13K words |
| 2025-08-07 | 2025-06-30 | 0001516551-25-000049 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001516551-25-000042 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001516551-24-000110 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001516551-24-000070 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001516551-24-000055 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001516551-23-000100 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001516551-23-000044 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001516551-23-000041 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001516551-22-000040 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001516551-22-000022 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-19 | 0001628280-26-057804 | EDGAR | — |
| 2026-08-14 | 0001628280-26-056966 | EDGAR | — |
| 2026-04-03 | 0001628280-26-023699 | EDGAR | 5K words |
| 2026-03-19 | 0001628280-26-019878 | EDGAR | — |
| 2026-03-10 | 0001628280-26-016400 | EDGAR | — |
| 2026-02-20 | 0001628280-26-010186 | EDGAR | — |
| 2026-02-02 | 0001628280-26-004451 | EDGAR | — |
| 2025-12-23 | 0001628280-25-058729 | EDGAR | — |
| 2025-11-10 | 0001628280-25-051035 | EDGAR | — |
| 2025-10-06 | 0001628280-25-044223 | EDGAR | — |
202 total filings indexed. 170 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001516551 |
| Ticker | SKYE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.skyebioscience.com |
| Listed | 2014-02-24 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/SKYE (~200 tokens, structured JSON with cryptographic provenance)